Synapse - Alison Moskowitz

Results (355)

Phase I/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell non-Hodgkin lymphoma: Phase I results from the T-cell consortium

Meeting Abstract

Lunning, M.; Horwitz, S.; Mehta-Shah, N.; Moskowitz, A.; Advani, R.; Beaven, A.; Haverkos, B.; Lechowicz, M.; Oki, Y.; Zain, J.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era

Meeting Abstract

Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

Meeting Abstract

Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Meeting Abstract

Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Interim results from a Phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Meeting Abstract

Herrera, A. F.; Moskowitz, A. J.; Bartlett, N. L.; Vose, J. M.; Ramchandren, R.; Feldman, T. A.; Lacasce, A. S.; Ansell, S. M.; Moskowitz, C. H.; Fenton, K.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE

Meeting Abstract

Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Phase I/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma

Meeting Abstract

Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Where do the new drugs fit in for relapsed/refractory Hodgkin lymphoma?

Journal Article

Khan, N.; Moskowitz, A. J.
Current Hematologic Malignancy Reports (2017)

Fulltext@MSK | Save

Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma

Journal Article

Gopal, A. K.; Fanale, M. A.; Moskowitz, C. H.; Shustov, A. R.; Mitra, S.; Ye, W.; Younes, A.; Moskowitz, A. J.
Annals of Oncology (2017)

Fulltext@MSK | Save

Targeting histone deacetylases in T-cell lymphoma

Journal Article

Moskowitz, A. J.; Horwitz, S. M.
Leukemia and Lymphoma (2017)

Fulltext@MSK | Save